Phase II study of treatment of advanced ovarian cancer with folate-receptor-targeted therapeutic (vintafolide) and companion SPECT-based imaging agent (99mTc-etarfolatide)

Robert Morris; Richard Joyrich; R. Wendel Naumann; Neha Shah; Alan H. Maurer; H. William Strausś; J. Michael Uszler; James T. Symanowski; P. R. Ellis; Wael A. Harb

doi:10.1093/annonc/mdu024

Phase II study of treatment of advanced ovarian cancer with folate-receptor-targeted therapeutic (vintafolide) and companion SPECT-based imaging agent (99mTc-etarfolatide)

著者: Robert Morris, Richard Joyrich, R. Wendel Naumann, Neha Shah, Alan H. Maurer, H. William Strausś, J. Michael Uszler, James T. Symanowski, P. R. Ellis, Wael A. Harb - Annals of Oncology 2014 被引用: 113

Phase II study of treatment of advanced ovarian cancer with folate-receptor-targeted therapeutic (vintafolide) and companion SPECT-based imaging agent (99mTc-etarfolatide) | Litlas